Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04840602
Title Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

lymphoplasmacytic lymphoma

Waldenstroem's macroglobulinemia


Ibrutinib + Rituximab + Venetoclax

Ibrutinib + Rituximab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.